Schroder Investment Management Group
BCYC

Schroder Investment Management Group’s Bicycle Therapeutics BCYC Stock Holding History

Schroder Investment Management Group’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Hold
615,833
– – ﹤0.01% 878
2026
Q1 		$2.67M Buy
615,833
+31,063
+5% +$178K ﹤0.01% 879
2025
Q4 		$3.98M Buy
+584,770
New +$4.31M ﹤0.01% 794

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Schroder Investment Management Group's BCYC Position: Q2 2026 in Review

Schroder Investment Management Group held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 615,833 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #878.

Schroder Investment Management Group first reported a position in BCYC in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.98M in Q4 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Schroder Investment Management Group held 615,833 shares of Bicycle Therapeutics worth $2.56M as of Q2 2026.
  • Schroder Investment Management Group left its Bicycle Therapeutics share count unchanged in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #878 holding.
  • Schroder Investment Management Group first reported a position in Bicycle Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Schroder Investment Management Group's Bicycle Therapeutics position peaked at $3.98M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.